misoprostol and Peripheral-Vascular-Diseases

Misoprostol, the oral analogue of alprostadil was used for the treatment of 20 patients (aged 40-60) with peripheral arterial disease according to Fontaine's classification at stages IIa and IIb (PAD). All patients received 200 micrograms of misoprostol 3 times a day during a month. The therapy with misoprostol resulted in a clinical improvement in all patients. Elongation of pain free (before treatment 129 m +/- 78 m, after treatment 214 m +/- 109 m) and maximum walking distance (before treatment 304 m +/- 169 m, after treatment 471 m +/- 264 m) was observed. At the same time a shortening of the pain duration was noted (before treatment 100 sec +/- 37 sec, after treatment 71 sec +/- 23 sec). The ankle/arm pressure ratio (AAPR) and arterial blood flow increased in both limbs after 4 weeks of the treatment. Activation of the fibrinolytic system was seen in the course of the therapy (shortening of euglobulin clot lysis time-ECLT and increase in t-PA activity). The platelets became less sensitive to ADP and collagen after intake of misoprostol. The results justify administration of misoprostol as a new therapeutic agent for the treatment of patients with PAD.

Topics: Administration, Oral; Adult; Aged; Arm; Exercise Test; Fibrinolysis; Humans; Leg; Middle Aged; Misoprostol; Peripheral Vascular Diseases; Platelet Aggregation; Platelet Aggregation Inhibitors; Regional Blood Flow

The stable prostacyclin analogue-iloprost and prostaglandin E1 (Alprostadil) showed a beneficial effect on activated platelets and leukocytes, and thrombocyte and leukocyte vessel interaction and damaged endothelium, improving microvascular perfusion and were useful in treatment of patients with peripheral arterial disease. The 4 weeks therapy with misoprostol caused a clinical improvement in all 14 patients and resulted in vasorelaxation and showed antiplatelet and fibrinolytic effects.

Topics: Humans; Misoprostol; Peripheral Vascular Diseases; Regional Blood Flow

Misoprostol, the oral analogue of alprostadil, was used to treat 20 patients (aged 40-60 years) with peripheral arterial disease (PAD) according to Fontaine's classification at stages IIa and IIb. All patients received 200 micrograms of misoprostol 3 times a day during a month. The therapy with misoprostol resulted in clinical improvement in all patients. Elongation of pain-free (before treatment: 129 m +/- 78 m; after treatment: 214 m +/- 109 m) and maximum walking distance (before treatment: 304 m +/- 169 m; after treatment: 471 m +/- 264 m) was observed. At the same time, a shortening of the duration of pain was noted (before treatment: 100 sec +/- 37 sec; after treatment: 71 sec +/- 23 sec). The ankle/arm pressure ratio (AAPR) and arterial blood flow increased in both limbs after 4 weeks of treatment. Activation of the fibrinolytic system was seen in the course of therapy (shortening of euglobulin clot lysis time (ECLT) and increase in t-PA activity). The platelets became less sensitive to ADP and collagen after intake of misoprostol. The results justify administration of misoprostol as a new therapeutic agent for the treatment of patients with PAD.

Topics: Adult; Aged; Fibrinolytic Agents; Humans; Intermittent Claudication; Middle Aged; Misoprostol; Peripheral Vascular Diseases; Pilot Projects; Platelet Aggregation Inhibitors; Tissue Plasminogen Activator